{"id":18460,"date":"2026-08-19T16:19:57","date_gmt":"2026-08-19T16:19:57","guid":{"rendered":"https:\/\/nile1.com\/en\/?p=18460"},"modified":"2026-08-19T16:20:11","modified_gmt":"2026-08-19T16:20:11","slug":"bank-of-america-spends-250-million-annually-on-glp-1-coverage-as-ceo-defends-soaring-costs","status":"publish","type":"post","link":"https:\/\/nile1.com\/en\/2026\/08\/19\/bank-of-america-spends-250-million-annually-on-glp-1-coverage-as-ceo-defends-soaring-costs\/","title":{"rendered":"Bank of America Spends $250 Million Annually on GLP-1 Coverage as CEO Defends Soaring Costs"},"content":{"rendered":"

Bank of America<\/a> Corp. is spending $250 million or more annually to cover GLP-1<\/a> weight-loss medications for its employees, a major commitment that CEO Brian Moynihan defended as a highly valuable investment despite the soaring costs that have led other large corporations to scale back coverage.<\/p>\n

It\u2019s part of a wider $2 billion a year wellness package for employee healthcare at the $436 billion bank. Staffers may have to cover the premium or copay for their GLP-1s, but the Wall Street titan is picking up the rest of the bill, amounting to nearly a quarter of a billion dollars annually. And Moynihan says the health investment is worth it to support a healthier workforce.<\/p>\n

In an interview with CNBC, Moynihan noted that the bank, which employs approximately 213,000 people globally, views the expenditure as a preventative health measure. \u201cIt\u2019s lowering near-term incidents of heart issues for people taking, even if they don\u2019t have all the attributes,\u201d Moynihan said. \u201cThat\u2019s the payback.\u201d<\/p>\n

The chief executive even acknowledged that Bank of America may not fully realize all the long-term benefits. He noted that some Bank of America staffers on GLP-1s may not see the health upsides until later in life, years after they\u2019ve left the company, but he still believes in the investment.<\/p>\n

To support employees taking these medications, which include popular brands like Wegovy and Zepbound, Bank of America provides health coaches and closely monitors weight-loss progress. Moynihan described the program as “the right thing to do for your teammates” and stated, “We do it because we want to be the great place to work.”<\/p>\n

Bank of America\u2019s open-handed approach contrasts with other major employers grappling with the financial impact of GLP-1 coverage. According to a 2024 national survey by consulting firm Mercer<\/a>, while 44% of large employers with 500 or more workers now cover GLP-1 drugs for weight loss, a growing number are implementing strict utilization management criteria or dropping coverage entirely due to the budgetary strain.<\/p>\n

For example, professional services firm PwC announced earlier this year that it would stop covering GLP-1 medications solely for weight loss, citing rapidly rising costs, and would restrict coverage to established conditions like type 2 diabetes. Similarly, health insurer Cigna Group eliminated GLP-1 weight-loss coverage from its own employee health plan in July, and hospital operator HCA Healthcare discontinued weight-loss coverage in January after usage of the drugs on its employee plan surged by 90% in a single year.<\/p>\n

Even among Wall Street peers, strategies differ. JPMorgan Chase<\/a> & Co. continues to cover the medications for its workforce but requires employees to enroll in a supervised weight-management program to qualify, establishing a clinical hurdle that Bank of America’s program does not mandate in the same manner.<\/p>\n

\n

Read also:<\/h3>\n